DP
ABBV icon

Diadema Partners’s AbbVie ABBV Stock Holding History

Diadema Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,000
Closed -$8.88M – 104
2024
Q4 		$8.88M Buy
+50,000
New +$9.19M 3.81% 5

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Diadema Partners's ABBV Position: Q1 2026 in Review

Diadema Partners opened a new position in AbbVie (ABBV) in Q1 2026: 24,058 shares worth $5.23M. The stake represents 0.89% of the portfolio and ranks #37 among its holdings. This is a return to the name: Diadema Partners previously reported a position in ABBV as recently as Q4 2024.

Diadema Partners first reported a position in ABBV in Q4 2024 and has held it in 2 quarters since. The position peaked at $8.88M in Q4 2024. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Diadema Partners held 24,058 shares of AbbVie worth $5.23M as of Q1 2026.
  • AbbVie was a new Diadema Partners position in Q1 2026.
  • AbbVie made up 0.89% of Diadema Partners's portfolio in Q1 2026, its #37 holding.
  • Diadema Partners first reported a position in AbbVie in Q4 2024 and has held it in 2 quarters since.
  • Diadema Partners's AbbVie position peaked at $8.88M in Q4 2024.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.